News | October 28, 2024
Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
Indoco is comprehensively working on the remedial action plan
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Subscribe To Our Newsletter & Stay Updated
